Addiction

Bay Area’s Horizon Treatment Services Receives Over $1 Million in Grants for Medication-Assisted Treatment

Grants Support Addition of Medication-Assisted Treatment Capacity in Detox & Residential Facilities, Paving the Way for Better Patient OutcomesHAYWARD, CA…

2 years ago

STR Behavioral Health to Open Mental Health Residential Services in Pennsylvania

BRENTWOOD, TN / ACCESSWIRE / March 14, 2024 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and…

2 years ago

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"),…

2 years ago

Avenues Recovery Centers in Louisiana Designated as Blue Distinction(R) Centers

Avenues Recovery Center's Two Louisiana Facilities Designated as Blue Distinction® Centers for Substance Use Treatment and RecoveryNEW ORLEANS, LA /…

2 years ago

Onsite Launches Outpatient Services at Onsite Wellness House in Nashville

Onsite Wellness House brings the best of Onsite and Milestones to those in Nashville and surrounding areas while minimizing disruption…

2 years ago

We Heart You: Recovery in Our Community Event 2024

What: We Heart You: Recovery in Our Community EventWhen: Wednesday, March 13, 12:00-5:00 PM(Welcome at 12:30 PM, Keynote speaker from…

2 years ago

Avenues Expands Its Services to Colorado

Avenues Recovery Center Opens New 130- Bed Facility in Aurora, ColoradoAURORA, CO / ACCESSWIRE / March 5, 2024 / Avenues…

2 years ago

Safe Supply Streaming Announces Closing of the Safety Strips Stake Acquisition and Its Accelerated Commercialization

Toronto, Ontario--(Newsfile Corp. - March 4, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply"…

2 years ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation…

2 years ago